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Background Patients with inﬂammatory bowel disease (IBD) show an increased risk of developing cytomegalovirus (CMV)
disease because of immunosuppressive medication and malnutrition. Here, we aimed to investigate the prevalence and clinical
characteristics of CMV disease in our cohort of IBD patients.
Patients and methods We carried out a retrospective analysis of 1023 IBD patients treated at our IBD clinic at the University
Hospital Zurich between 2007 and 2014. CMV disease was deﬁned as a positive immunohistochemistry for CMV and 14 patients
were identiﬁed.
Results The prevalence of CMV disease in our IBD cohort was 1.37%. Twelve patients had ulcerative colitis and two had
Crohn’s disease with colonic involvement. All patients who developed CMV disease received immunosuppressive medication or,
as in one case, had HIV infection. The most used immunosuppressive medications were steroids and azathioprine. The most
common therapeutic strategy was the consecutive use of ganciclovir and valganciclovir. Ten patients recovered and two were
treatment refractory; among these, one required colectomy and two had a relapse.
Conclusion CMV disease may inﬂuence the clinical course of IBD. There is probably an association between CMV disease and
IBD-speciﬁc medication. Risk factors, epidemiology and therapeutic strategy need to be further investigated. Eur J Gastroenterol
Hepatol 28:1329–1334
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Introduction
Cytomegalovirus (CMV) is a member of the herpes-virus
family, causing a common and usually asymptomatic viral
infection, occurring in 40–100% of adults. Despite a high
prevalence of CMV in the general population, clinically
signiﬁcant CMV disease mainly occurs in immunocom-
promised patients [1]. It is important to distinguish CMV
infection, where an individual is positive by PCR or ser-
ologic analysis, from CMV disease, such as CMV colitis or
CMV retinitis, where the virus causes signiﬁcant clinical
symptoms [2].
Haematoxylin and eosin (H&E), immunohistochem-
istry (IHC) and tissue PCR are the methods of choice to
determine the presence of CMV in colon tissue as they are
likely to be more appropriate to evaluate CMV involve-
ment in colitis than antigenaemia, IgM and leucocyte DNA
PCR testing [3]. H&E staining typically shows enlarged
cells with large eosinophilic inclusions. The presence of
these cells indicates not only infection, but is associated
with colitis that is poorly responsive to standard inﬂam-
matory bowel disease (IBD) therapy, providing a diag-
nostic tool for CMV disease, namely, CMV colitis [4].
H&E staining has a high speciﬁcity (92–100%), but its
sensitivity is in the range of 10–87% [3]. IHC has a very
good sensitivity (78–93%) and uses monoclonal anti-
bodies to identify the CMV early antigen. The speciﬁcity
ranges between 92 and 100% [4].
IHC is important in the routine evaluation of IBD
patients with severe disease before proceeding with step-up
medical treatment or even surgery [5]. The clinical sig-
niﬁcance of a positive PCR of colonic tissue without other
histological signs of infection remains unclear. The pre-
sence of viral DNA without histological features is likely to
represent low-level reactivation of latent CMV infec-
tion [3].
Data on the prevalence of CMV colitis complicating
IBD are sparse and further investigations are necessary to
draw conclusions. A recent review from 2015 reported
that the actual data cannot provide clear answers, mainly
because of selection bias and different diagnostic methods
[6]. However, probably a higher prevalence of CMV in
steroid-resistant patients exists, with a female pre-
ponderance [5].
Nevertheless, IBD patients are at an increased risk for
active CMV disease [4]. This predisposition is likely
because of immunosuppression, mainly as a result of
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immunosuppressive therapy and poor nutrition, possible
impairment of natural killer function and CMV tropism
for sites of inﬂammation [1,7]. A common question is
whether CMV leads to the development of IBD or whether
it only worsens disease severity. The ﬁrst theory is an
unlikely option, considering that CMV disease is rare in
patients with mild to moderate ulcerative colitis (UC) and
Crohn’s disease (CD) [3]. Studies on CMV, UC and
steroid-resistance showed considerable heterogeneity, but
there is sufﬁcient evidence to show that CMV disease
increases the biological severity of colitis [2]. Some authors
noted that patients with CMV had a higher mortality and
colectomy rate [7]. Furthermore, it remains to be investi-
gated in which cases a speciﬁc treatment is needed and
which cases feature a spontaneous remission.
The aim of this study was to characterize patients with
CMV disease as diagnosed by a positive IHC for CMV
from a total of 1023 patients in our IBD clinic at the
University Hospital Zurich.
Patients and methods
We retrospectively identiﬁed 14 patients from a cohort of
1023 patients from the IBD clinic at the University
Hospital Zurich treated between 2007 and 2014, who had
a positive IHC for CMV after their diagnosis of either UC
or CD in the context of ongoing disease activity, except for
one case, where CMV was found in the stomach. An initial
screening of the cohort, where we searched for the term
‘CMV’ in the electronic medical records, limited the results
to 311 patients. From this group, we selected only those
patients who ﬁnally had a positive CMV IHC result and a
positive diagnosis of UC or CD.
We collected the following data: age, sex, ﬁrst diagnosis
of IBD, Vienna classiﬁcation, presence of complications
(ﬁstulae and stenosis), surgical interventions, degree of
colon involvement for UC, IBD-speciﬁc therapy: use of
steroids and other immunosuppressive therapy alone or in
combination [e.g. corticosteroids, budesonide, purine
analoga (azathioprine, 6-mercaptopurine), methotrexate,
antitumour necrosis factor alpha inhibitors (adalimumab,
inﬂiximab, certolizumab pegol) and anti-integrin inhibitors
as vedolizumab], CMV-speciﬁc data: time of positive
CMV IHC, results of other diagnostic tests (IgG and IgM
serology, blood PCR, biopsy PCR, faecal PCR and H&E
staining), presence of CMV disease relapses, conditions of
treatment (as an inpatient or an outpatient), immunosup-
pressive therapy at the time of positive CMV IHC and
treatment outcome of CMV disease, in particular, recov-
ery. The presence of CMV relapses was deﬁned as a second
positive CMV IHC testing after conclusion of therapy and
improvement of symptoms. Recovery was determined
either by hospital exit, stopping of antiviral medication or
a negative IHC after a previous positive one.
In terms of the results of the PCR tests, we considered
only those who had a relationship with a positive result of
a IHC; therefore, we excluded tests performed more than
2 weeks before IHC and tests performed after or during
CMV treatment. For the two cases with relapses, only data
on the primary event are considered in the tables; the
details on the second event are discussed separately in the
results.
The patient information that was collected was anon-
ymized and deidentiﬁed before analysis and for
publication.
Institutional review board statement
The cohort study was approved by the local ethical com-
mittees (IRB approval number: EK-1755, approved on 1
March 2010 by the Cantonal Ethics Committee of the
Canton Zürich, Switzerland).
Results
Prevalence of CMV disease and patients’ characteristics
From our IBD cohort, 396 (38.7%) patients had UC, 601
(58.8%) had CD and 26 (2.5%) were IBD unclassiﬁed. In
terms of sex, 536 (52.4%) patients were men and 487
(47.6%) were women. From the 1023 patients, only 14
were diagnosed with a CMV-positive IHC between 2007
and 2014.
This contributed towards a prevalence of 1.37%. Of the
entire cohort, of the 14 patients with a positive CMV IHC,
12 had CMV colitis, one had CMV proctitis and one had
detectable CMV in the stomach. This case was described
as a chronic and generalized CMV infection including a
history of CMV pneumonia; in our study, it was classiﬁed
as refractory to therapy.
General disease characteristics and demographic data of
the patients are summarized in Table 1. Of the 14 patients,
ﬁve were women and nine were men. A higher proportion
of the patients had UC and only two had CD. The average
age at the diagnosis of IBD was 36 years, with little dif-
ferences between CD (32 years) and UC (37 years). The
average age of the patients was 39 years at the time of
positive IHC. One of the two patients with CD had ﬁstu-
lizing disease without luminal stenosis. Two out of the 12
patients with UC had undergone IBD-related surgery,
seven had pancolitis, four had a left-sided colitis and one
had proctitis. Thirteen of 14 patients had received immu-
nosuppressive therapy. One patient did not receive any
IBD-speciﬁc therapy because at the time of positive IHC,
the diagnosis of UC was not provided; nonetheless, the
clinical symptoms were already present. The diagnosis of
UC was made histologically 3 months after CMV infection
Table 1. Patient and disease characteristics
Patient and disease characteristics Total CD UC
Number 14 2 12
Female 5 1 4
Male 9 1 8
Average age at ﬁrst diagnosis of IBD (years) 35.71 32 36.33
Average age at ﬁrst positive IHC (years) 39.07 38 39.25
Fistulizing disease 1 1
Stenosis 0 0
History of surgery 2 0 2
Immunosuppressive therapy 13 2 11
Colitis disease extent 12 12
Pancolits 7 7
Left-sided colits 4 4
Proctitis 1 1
Treatment setting 14 2 12
Inpatients 11 2 9
Outpatients 3 0 3
CD, Crohn’s disease; IBD, inﬂammatory bowel disease; IHC, immunohistochem-
istry; UC, ulcerative colitis.
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after colitis reoccurred and recurrent CMV infection could
be ruled out. The diagnosis emerged later, but it explained
the patient’s previous problems. Nevertheless, the patient
was immunocompromised because of HIV infection.
Diagnostic tests for CMV detection
The results of all the diagnostic tests for CMV are pre-
sented in Table 2. All the patients included in the study had
a positive IHC for CMV as the diagnostic criterion on
which the diagnosis was ﬁnally based; here, we also
describe the results of additional diagnostic tests that were
performed. H&E staining showed positive results in eight
out of 14 patients who performed the test. Faecal PCR was
only performed in two patients, with positive results in
both. Biopsy PCR was tested in seven patients and was
always positive. Blood PCR was also tested in seven cases,
showing positivity in ﬁve patients; blood PCR was per-
formed on EDTA blood or citrate blood. Serology
(enzyme-linked immunosorbent assay) for IgM and IgG
was obtained in four patients, providing a positive result
for IgG in all cases, but interestingly, only for one patient
for IgM, probably reﬂecting a primoinfection or a
reactivation.
All IHC-positive biopsies for CMV were obtained from
inﬂamed mucosa. The average number of biopsies that was
taken was 8 (2–24 biopsies). In three cases where IHC for
CMV from inﬂamed mucosa was positive, biopsies from
noninﬂamed mucosa were also taken, which were all IHC
negative for CMV. In all patients, the CMV diagnosis was
made after the diagnosis of IBD. In six patients, the diag-
nosis of CMV was made under treatment with aza-
thioprine (Table 3).
IBD treatment
Medications at the time of positive IHC are shown in
Table 3. In six patients, the CMV diagnosis was made
under treatment with azathioprine (Table 3). In three
cases, CMV diagnosis was made in patients who had a
personal history of azathioprine therapy (>1 year after
azathioprine therapy in two patients and duration
unknown in one patient). The two most common medi-
cations at the time of positive IHC were steroids and
azathioprine. Less common medications were inﬂiximab
and budesonide; adalimumab and 6-mercaptopurine were
only used by two different patients. Azathioprine com-
bined with steroids and inﬂiximab with steroids were the
two most common combinations of medications, used in
three patients each. Steroids alone and the combination of
azathioprine, budesonide and steroids each accounted for
the therapy of two patients. Ten patients took mesalazine
at the time of positive CMV IHC.
Treatment and course of CMV disease
Data on CMV-speciﬁc therapy are summarized in Table 4.
Most patients were treated consecutively with intravenous
ganciclovir, followed by oral valganciclovir, four patients
were treated only with oral valganciclovir (three of them
were treated as outpatients) and two patients were treated
only with intravenous ganciclovir. The standard intrave-
nous ganciclovir dose was 5 mg/kg bodyweight every 12 h
and the oral valganciclovir dose was 900mg 2× daily, or
adopted to kidney function if necessary.
Details on therapy outcome are shown in Fig. 1. Six out
of eight patients treated with intravenous ganciclovir, fol-
lowed by oral valganciclovir showed remission, one
patient developed a relapse and one patient was therapy
refractory. One of the patients treated only with intrave-
nous ganciclovir developed a relapse; the other required a
total colectomy with ileostomy. All four patients treated
with valganciclovir achieved recovery.
Eleven patients were primarily treated as inpatients and
the other three as outpatients (all treated with valganci-
clovir). Ten patients recovered from disease, two were
therapy refractory, one of these patients requiring colect-
omy, and two developed a relapse. One of the two
therapy-refractory patients had CD and had a chronic and
generalized CMV infection treated primarily with ganci-
clovir, followed by a long-term valganciclovir regimen;
however, it must be noted that this patient was not tested
for CMV colitis, but the virus was found in the stomach.
Table 2. Diagnostic methods for CMV
Diagnostic methods Positive tests/total of tests performed CD UC
IHC 14/14 2/2 12/12
Histology (H&E) 8/14 1/2 7/12
Faecal PCR 2/2 2/2
Biopsy PCR 7/7 7/7
Blood PCR 5/7 1/1 4/6
IgG serology 4/4 4/4
IgM serology 1/4 1/4
CD, Crohn’s disease; CMV, cytomegalovirus; H&E, haematoxylin and eosin; IHC,
immunohistochemistry; UC, ulcerative colitis.
Table 3. IBD-speciﬁc medication taken at the time of positive CMV IHC
Medication at the time of CMV-positive IHC Total CD UC
Number 14 2 12
Steroids 13 2 11
Azathioprine 6 2 4
Budenoside 3 1 2
Inﬂiximab 4 0 4
Adalimumab 1 1 0
6-MP 1 0 1
Combinations of medication/single therapies 14 2 12
Azathioprine and steroids 3 0 3
Inﬂiximab and steroids 3 0 3
Azathioprine, steroids and budenoside 2 1 1
Steroids 2 0 2
Azathioprine, steroids and adalimumab 1 1 0
Inﬂiximab, steroids and 6-MP 1 0 1
Budenoside 1 0 1
No IBD-speciﬁc treatment 1 0 1
CD, Crohn’s disease; CMV, cytomegalovirus; IBD, inﬂammatory bowel disease;
IHC, immunohistochemistry; 6-MP, 6-mercaptopurine; UC, ulcerative colitis.
Table 4. Treatment outcome and antiviral medication
Treatment outcome and antiviral medication Total CD UC
Total 14 2 12
Ganciclovir 2 0 2
Valganciclovir 4 0 3
Ganciclovir and valganciclovir 8 2 6
Recovery 10 1 9
Relapse 2 0 2
Therapy refractory 1 1 0
Therapy refractory and colectomy 1 0 1
CD, Crohn’s disease; UC, ulcerative colitis.
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The other patient, who had UC, presented to the hospital
for a steroid-refractory ﬂare and was treated with ganci-
clovir without a positive effect on the symptoms, and then
required a colectomy.
Relapses
Overall, two UC patients out of 14 IBD patients developed
relapses, deﬁned as a second positive IHC after the com-
pletion of antiviral therapy and improvement of symp-
toms. The interval between the two positive IHC was 241
and 91 days, respectively. One patient was treated the ﬁrst
time with ganciclovir, showing an improvement in the
clinical symptoms and general conditions; the relapse was
treated with ganciclovir and valganciclovir. The other
patient was treated primarily with ganciclovir and val-
ganciclovir, achieving an improvement of the clinical
course; the relapse resolved spontaneously and no antiviral
treatment was required.
Discussion
In our retrospective analysis of CMV disease, we found a
prevalence of 1.37%; the most commonly used medica-
tions at the time of positive CMV IHC were the steroids
azathioprine and inﬂiximab. Most patients were treated
with both intravenous ganciclovir and oral valganciclovir.
The prevalence of CMV disease varies markedly
between UC and CD [8]. Studies on patients with inactive
or mild–moderate UC did not show an increased risk of
CMV colitis, diagnosed with H&E and IHC. The most
extensive literature exists on severe and/or steroid-
refractory UC, terms that are used interchangeably and
are not clearly deﬁned. Therefore, ﬁndings are difﬁcult to
interpret [8]. The prevalence of CMV diagnosed with HE
or IHC varies considerably even between the UC patients,
ranging from 0.5% in severe steroid-resistant colitis to 3%
in severe colitis. The highest values were found in patients
who needed an urgent colectomy, where the prevalence
ranged between 11.5 and 27% [8].
Nevertheless, histological prevalence (H&E or IHC) of
CMV in UC patients has been reported to be between 4.5
and 13.8% according to another systematic review [6].
The large heterogeneity of the results can be explained
mainly by selection bias and heterogeneity in diagnostic
methods [6]. Even if seropositivity in CD patients is as high
as in other populations, CMV disease is rare in these
patients. CMV disease diagnosed by IHC was not detected
in most studies in CD patients [8].
The somewhat low prevalence of 1.37% in our large
single-centre IBD cohort might be attributed to the fact
that we included both UC and CD patients of our cohort,
calculating the prevalence on a population composed not
only of patients with severe or therapy-refractory diseases
but including every IBD patient treated in our tertiary
centre between 2007 and 2014. However, for daily prac-
tice, this also means that CMV prevalence overall is rather
small, even in a tertiary referral centre. Some theories
attempt to explain the differences in CMV disease pre-
valence between UC and CD [9]; however, these results
were obtained from small studies and should be inter-
preted with caution [8]. One explanation suggests that in
IBD patients, tumour necrosis factor could be associated
with CMV infection or reactivation. In contrast to tumour
necrosis factor, interferon-γ (IFNγ), which is produced
from CD4+T-cells, could suppress CMV reactivation. CD
is considered a Th1-type inﬂammatory process with high
expression of IFNγ. Therefore, the differences in inﬂam-
matory mechanisms could explain the different pre-
valences of CMV disease in UC and CD [8]. These ﬁndings
could explain the fact that inﬂiximab does not seem to
affect CMV reactivation, as found in a prospective study in
CD, supporting the safety of short-term treatment [10].
Similarly, D’Ovidio et al. [11] found that inﬂiximab did
not appear to induce progression from CMV infection to
disease.
It remains to be determined whether IHC is the best
diagnostic test to decide whether it is necessary to undergo
a speciﬁc therapy or not, mostly because quantitative real-
time PCR in inﬂamed mucosa has a better sensitivity to
detect CMV, even if it can lead to false-positive results.
After a systematic review, Ayre et al. [2] considered that
only detection by histopathology seemed to be clinically
relevant and appropriate for speciﬁc therapy with antiviral
medications. Nevertheless, Yoshino et al. [12] concluded
Ganciclovir and
valganciclovir
n=8
Therapy refractory
n=1
Relapse
n=1
Remission
n=6
Valganciclovir
n=4
Remission
n=4
Ganciclovir
n=2
Relapse
n=1
Colectomy
n=1
Fig. 1. Details on treatment outcome.
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that the use of quantitative real-time PCR for detecting
CMV-DNA in inﬂamed mucosa was appropriate for the
diagnosis and the consecutive treatment of CMV infection.
So far, it is recommended in the current guidelines by the
European Crohn’s and Colitis Organization to use IHC or
PCR as diagnostic tests for CMV colitis in IBD patients
[13]. Our study showed that biopsy PCR was performed in
seven patients and was always positive; this result is in
agreement with the high sensitivity of the test.
For CMV therapy, in the literature, there is an ongoing
debate in which cases a speciﬁc treatment is needed and
which cases feature a spontaneous remission. Interestingly,
a recent study found that IBD patients with a high density
of viral inclusions in the biopsy sample beneﬁt from anti-
viral therapy [14]. Roblin et al. [15] found a relationship
between CMV DNA load in inﬂamed tissue and resistance
to three successive treatments (steroids, inﬂiximab and
cyclosporine). A study suggested that the absence of large
ulcers in patients with active UC and a positive mucosal
viral assay are signs of a latent CMV infection, therefore
not requiring an antiviral therapy. The authors suggested
that large controlled trials are needed to conﬁrm the use-
fulness of antiviral therapy in patients with deep colonic
ulcers [16]. A randomized trial in adult solid organ
transplant recipients with CMV disease showed that oral
valganciclovir is not inferior to intravenous ganciclovir
and has a comparable safety for the treatment of CMV
disease [17]. European Crohn’s and Colitis Organization
guidelines recommend treatment with ganciclovir and an
eventual switch to valganciclovir when CMV is detected in
colon tissue, and consider that stopping of immunosup-
pressive therapy is necessary only in cases of systemic
CMV reactivation [13].
As shown in other studies, we found a high proportion
of patients who were treated with corticosteroids while
suffering from CMV disease [3]. Interestingly, we found
that all patients had received immunosuppressive therapy
or were immunocompromised. The majority of patients
received azathioprine, steroids and inﬂiximab in
combination.
Jacobson et al. [18] found a prevalence of gastro-
intestinal disease caused by CMV in 2.2% of AIDS
patients. Santos et al. [19] analysed a cohort of lung
transplant recipients and found that delayed-onset and
early-onset CMV disease occurred in 13.7 and 3.3% of
patients. CMV colitis is rare in UC patients without ster-
oids or other immunomodulators as IBD therapy. CMV
colitis in healthy individuals is extremely rare [2]. These
results suggest that CMV disease needs some degree of
immunosuppression to evolve, and that in IBD, both
therapy and disease itself contribute towards CMV reac-
tivation and disease.
Overall, the vast majority of CMV disease occurs in
patients with UC rather than CD. Most patients who
develop a CMV disease are treated with immunosuppres-
sive medication. Testing for CMV disease should be per-
formed in all patients who have a deteriorated course of
IBD, especially in patients with severe and therapy-
refractory IBD.
Our study has several strengths and limitations such as
the selection of only one tertiary centre and use of a ret-
rospective approach. However, our main strength is the
lack of bias in the selection of the patients in their
diagnosis of UC or CD and the extent of the disease. A
limitation could be that it cannot clearly be excluded that
CMV is a bystander and not the contributor towards the
colitis in the cases presented. What speaks against this is
that all IHC CMV-positive biopsies were obtained from
inﬂamed mucosa and that in the three cases where biopsies
were obtained from noninﬂamed mucosa, these were all
IHC negative for CMV. Another limitation is that we did
not have information on the disease course of the patients
who did not have CMV colitis.
In conclusion, on the basis of the existing literature and
on our data, it would be of interest to further investigate
CMV disease and its treatment to conﬁrm the results
obtained so far.
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